UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~July 261, 2026 ~~(May 19, 2026)~~

20/20 BIOLABS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-43128		57-2272107
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

15810 Gaither Road, Suite 235, Gaithersburg, MD		20877
(Address of principal executive offices)		(Zip Code)

240-453-6339

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01		AIDX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 37.0301 ~~Material~~Regulation ~~Modification~~FD ~~to Rights of Security Holders.~~Disclosure

~~On May 19, 2026, the Board of Directors of~~ 20/20 Biolabs, Inc. (the “Company”) intends ~~adopted~~to ~~Amendment~~use ~~No.~~the 1materials attached to ~~the~~this ~~Company’s Amended~~report ~~and~~as ~~Restated~~Exhibit ~~Bylaws~~99.1 ~~(the~~in ~~“Amendment”),~~an ~~pursuant~~investor towebinar ~~which~~on ~~Section~~July 21, 2026.5 The furnishing of these ~~the~~materials ~~Company’s~~is ~~Amended~~not ~~and~~intended ~~Restated Bylaws~~to ~~was~~constitute ~~amended~~a torepresentation ~~reduce~~that such furnishing is required by Regulation FD or other securities laws, or that the ~~quorum~~presentation ~~required~~materials ~~for~~include amaterial ~~meeting~~investor ofinformation ~~stockholders~~that ~~from~~is anot ~~majority~~otherwise ofpublicly available. In addition, the ~~shares~~Company ~~outstanding~~does not assume any obligation to ~~one-third of~~update ~~the~~such ~~shares~~information ~~outstanding.~~in the future.

The ~~foregoing~~information ~~description~~in ofthis ~~the~~report ~~Amendment~~(including ~~does~~Exhibit ~~not~~99.1) ~~purport~~is furnished pursuant to beItem ~~complete~~7.01 and isshall ~~qualified~~not inbe ~~its~~deemed ~~entirety~~“filed” byfor ~~reference~~purposes toof ~~the~~Section ~~full~~18 ~~text~~ of the ~~Amendment~~Securities Exchange ~~filed~~Act of 1934, as ~~Exhibit~~amended, ~~3.2~~or otherwise subject to the liabilities of such Section. The information in this report, ~~which~~will isnot ~~incorporated~~be deemed ~~herein~~an byadmission ~~reference~~as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 59.0301 ~~Amendments~~Financial toStatements ~~Articles~~and ~~of Incorporation or Bylaws; Change in Fiscal Year~~Exhibits.

~~The~~(d) ~~information set forth in Item 3.03 above is incorporated herein in its entirety.~~Exhibits

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description of Exhibit
99.1		Investor Presentation, July 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

~~(d) Exhibits~~ 1

Exhibit No.		Description of Exhibit
3.1		Amended and Restated Bylaws of 20/20 Biolabs, Inc. (incorporated by reference to Exhibit 2.3 to the Annual Report on Form 1-K filed on July 6, 2020)
3.2		Amendment No. 1 to Amended and Restated Bylaws of 20/20 Biolabs, Inc.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

1Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGNATURES

Date: July 1, 2026	20/20 BIOLABS, INC.

	/s/ Jonathan Cohen
	Name:	Jonathan Cohen
	Title:	Chief Executive Officer

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~ 2

Date: May 26, 2026	20/20 BIOLABS, INC.
	/s/ Jonathan Cohen
	Name: Jonathan Cohen
	Title: Chief Executive Officer

Filing Compare · 20/20 Biolabs, Inc.